Theme |
Current Therapy of IBD |
Title |
Optimization of Apheresis for Ulcerative Colitis and Crohn's Disease |
Author |
Yoko Yokoyama |
Division of Lower Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine |
Author |
Ken Fukunaga |
Division of Lower Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine |
Author |
Takayuki Matsumoto |
Division of Lower Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine |
[ Summary ] |
There have been recent advancements in therapies for inflammatory bowel disease (IBD). GMA was established as a treatment for refractory Crohn's disease (CD) patients in 2009. Intensive treatment with CAP was accepted for UC patients in 2010. We demonstrated that UC out-patients withmoderate activity are good candidates for weekly LCAP. A close correlation between UC duration and GMA response has been proven retrospectively. We have also used weekly GMA to treat refractory CD, especially biologic-refractory conditions. CAP is the original Japanese adjunct therapy for refractory IBD. To provide optimal care we must prescribe the best means to reinforce clinical efficiency for eachform of CAP. |